Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECx: Pembrolizumab Registry in Cervical Cancer
NCT07645625Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in Cervical Cancer (CC) (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Progression-Free Survival at 12 months. Started May 2026; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07645625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645625.